These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21818844)

  • 1. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
    Danen-van Oorschot AA; Kuipers JE; Arentsen-Peters S; Schotte D; de Haas V; Trka J; Baruchel A; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2012 May; 58(5):715-21. PubMed ID: 21818844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
    Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
    Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Van den Heuvel-Eibrink MM; De Menezes RX; Reinhardt D; Hollink IH; Arentsen-Peters ST; van Wering ER; Kaspers GJ; Cloos J; de Bont ES; Cayuela JM; Baruchel A; Meyer C; Marschalek R; Trka J; Stary J; Beverloo HB; Pieters R; Zwaan CM; den Boer ML
    Haematologica; 2011 Feb; 96(2):221-30. PubMed ID: 20971820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of specific microRNA and their targets in acute myeloid leukemia.
    Cammarata G; Augugliaro L; Salemi D; Agueli C; La Rosa M; Dagnino L; Civiletto G; Messana F; Marfia A; Bica MG; Cascio L; Floridia PM; Mineo AM; Russo M; Fabbiano F; Santoro A
    Am J Hematol; 2010 May; 85(5):331-9. PubMed ID: 20425795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Tejero R; Díaz T; Pratcorona M; Tormo M; Ribera JM; Escoda L; Duarte R; Gallardo D; Heras I; Queipo de Llano MP; Bargay J; Monzo M; Sierra J; Navarro A; Esteve J;
    Leukemia; 2014 Apr; 28(4):804-12. PubMed ID: 24072101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.
    Seyyedi SS; Soleimani M; Yaghmaie M; Ajami M; Ajami M; Pourbeyranvand S; Alimoghaddam K; Akrami SM
    Tumour Biol; 2016 Apr; 37(4):4841-7. PubMed ID: 26526573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.
    Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM
    Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
    Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia.
    Coskun E; von der Heide EK; Schlee C; Kühnl A; Gökbuget N; Hoelzer D; Hofmann WK; Thiel E; Baldus CD
    Leuk Res; 2011 Feb; 35(2):208-13. PubMed ID: 20570349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population.
    Yatsenko Y; Kalennik O; Maschan M; Kalinina I; Maschan A; Nasedkina T
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e100-8. PubMed ID: 23511494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis.
    Chen S; Chen Y; Zhu Z; Tan H; Lu J; Qin P; Xu L
    Int J Med Sci; 2020; 17(9):1269-1280. PubMed ID: 32547322
    [No Abstract]   [Full Text] [Related]  

  • 17. Classification of pediatric acute myeloid leukemia based on miRNA expression profiles.
    Obulkasim A; Katsman-Kuipers JE; Verboon L; Sanders M; Touw I; Jongen-Lavrencic M; Pieters R; Klusmann JH; Michel Zwaan C; van den Heuvel-Eibrink MM; Fornerod M
    Oncotarget; 2017 May; 8(20):33078-33085. PubMed ID: 28380436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
    Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
    Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.